In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

CG Oncology, Inc.'s promising bladder cancer therapy, strong financials, and unique therapeutic profile make it a compelling ...

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

Drs. Indraneel Banerjee and John S. Banerji, urologists at Penn Highlands Urology in DuBois, have reached a significant ...

It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic ...

Ferring Pharmaceutical officially opened its new 12,000-square-foot gene therapy manufacturing facility located within its US ...

Sam S. Chang MD, MBA, discusses the findings for mitomycin in for low-grade intermediate-risk nonmuscle-invasive bladder ...

A Bridgeport resident says the CT DOC's failure to provide timely treatment led to 28 rounds of chemotherapy and the removal ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in near term. Click ...